Grifols S.A. ADR (GRFS)
NASDAQ: GRFSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
GRFS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.10B
- P/E (TTM)
- 9.74
- Forward P/E
- 5.20
- EPS (TTM)
- $0.77
- Dividend yield
- 1.40% ($0.00)
- Ex-dividend date
- Jul 2, 2026
- 52-week range
- 6.96 – 9.90
- Day range
- 7.44 – 7.56
- Volume / Avg
- 260.70K / 583.27K
- Beta
- —
- Shares outstanding
- 258.22M
52-week range
GRFS stock today
Grifols S.A. (GRFS) closed at $7.50 on Oct 7, down 0.27% (-$0.02), versus the S&P 500's 0.22% decline. Trading was light, with 260.70K shares changing hands, about 45% of the average daily volume. At this level, GRFS sits near the bottom of its 52-week range of $6.96 to $9.90: 24.2% below the high, set on Nov 4, 2025 and 7.8% above the low.
GRFS is down 19.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 21.8%. Grifols S.A. trades at 9.7x its trailing twelve-month earnings per share of $0.77. Its forward P/E of 5.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Grifols S.A.
Company profileGrifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jose Ignacio Abia Buenache
- Headquarters
- Barcelona
- Employees
- 25,258
- Website
- grifols.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$10.87+44.93%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Dividends
Dividend history- Annual dividend
- $0.00
- Dividend yield
- 1.40%
- Last payment
- $0.094
- Ex-dividend date
- Jul 2, 2026
Grifols S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs GRFS |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs GRFS |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs GRFS |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs GRFS |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs GRFS |
| DNTHDianthus Therapeutics Inc. | 84.88 | -0.61% | $4.75B | vs GRFS |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs GRFS |
| LGNDLigand Pharmaceuticals Incorporated | 293.26 | -1.24% | $5.85B | vs GRFS |
Indexes, lists and sector
Appears in lists
Grifols S.A. stock FAQ
What is Grifols S.A.'s stock price today?
GRFS last traded at $7.50 as of Oct 7, 4:00 PM EDT, down 0.27% on the day. Prices are delayed at least 15 minutes.
Does Grifols S.A. pay a dividend?
Yes. Grifols S.A. pays $0.00 per share annually, a 1.40% yield. The most recent dividend of $0.094 had an ex-dividend date of Jul 2, 2026.
What is GRFS's P/E ratio?
GRFS trades at a trailing P/E ratio of 9.74 and a forward P/E of 5.20.
Who is Grifols S.A.'s CEO?
Mr. Jose Ignacio Abia Buenache is the chief executive officer of Grifols S.A. ADR, which has about 25,258 employees.
Has GRFS ever split its stock?
Yes. The most recent GRFS stock split was a 2-for-1 split on Jan 4, 2016, one of 3 splits on record.
What is the GRFS 52-week high?
The 52-week high for GRFS is $9.90 and the 52-week low is $6.96. The stock is currently 24.2% below its high.